StreetInsider.com News Articles

OKYO Pharma Ltd. (OKYO) PT Lowered to $5 at H.C. Wainwright

Mon, 13 Jul 2026 06:40:53 -0400

(Updated - July 13, 2026 6:40 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on OKYO Pharma Ltd. (NASDAQ: OKYO) to $5.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "Last week, OKYO Pharma announced positive outcome from its Type D meeting with the FDA regarding the regulatory path and the design of a global Phase 3 trial of urcosimod for the treatment of neuropathic corneal pain (NCP). Notably, the Phase 3 NEPTUNE trial could support a potential single-trial registration strategy, subject to successful study results and continued FDA review. According to the protocol, NEPTUNE is a

OKYO Pharma Ltd. (OKYO) PT Lowered to $5 at H.C. Wainwright

Mon, 13 Jul 2026 06:40:53 -0400

(Updated - July 13, 2026 6:40 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on OKYO Pharma Ltd. (NASDAQ: OKYO) to $5.00 (from $7.00) while maintaining a Buy rating.

OKYO Pharma advances urcosimod into Phase 3 trial after FDA meeting

Wed, 08 Jul 2026 07:00:11 -0400

OKYO Pharma Limited (NASDAQ: OKYO) announced it received positive feedback from a U.S. Food and Drug Administration Type D meeting regarding its drug candidate urcosimod, and said it plans to advance the therapy into a global Phase 3 pivotal trial for neuropathic corneal pain.

The company said the FDA provided alignment on a single-dose Phase 3 study design and indicated the trial could support a potential single-trial registration pathway, subject to successful results and continued FDA review.

The trial, named NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), is planned to enroll approximately 111 subjects across the United States and

Form 6-K OKYO Pharma Ltd For: Jul 08

Wed, 08 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260708/26744119.html

Form 6-K OKYO Pharma Ltd For: Jul 08

Wed, 08 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260708/26744119.html

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

Wed, 08 Jul 2026 07:00:00 -0400

FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimod
Company unveils NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global trial in the United States and Europe
Study design finalized to enroll approximately 111 subjects in a 2:1 randomization of 0.05% urcosimod versus placebo
To address the significant unmet medical need, the company plans to seek FDA Breakthrough Therapy Designation (BTD), which may further accelerate the development and review pathway

LONDON and NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) --

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

Wed, 08 Jul 2026 07:00:00 -0400

FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimod
Company unveils NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global trial in the United States and Europe
Study design finalized to enroll approximately 111 subjects in a 2:1 randomization of 0.05% urcosimod versus placebo
To address the significant unmet medical need, the company plans to seek FDA Breakthrough Therapy Designation (BTD), which may further accelerate the development and review pathway

LONDON and NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) --

Form 6-K OKYO Pharma Ltd For: Jul 07

Tue, 07 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26738194.html

Form 6-K OKYO Pharma Ltd For: Jul 07

Tue, 07 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26738194.html

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

Tue, 07 Jul 2026 07:00:00 -0400

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026.

Details of the event are as follows:

Presenters: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: Thursday, July 9 at 8:30 AM ET

Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

Tue, 07 Jul 2026 07:00:00 -0400

Details of the event are as follows:

Presenters: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: Thursday, July 9 at 8:30 AM ET

Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper

Form 3 OKYO Pharma Ltd For: Mar 18 Filed by: Mantelli Flavio

Wed, 17 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260617/26660080.html

Form 3 OKYO Pharma Ltd For: Mar 18 Filed by: Mantelli Flavio

Wed, 17 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260617/26660080.html

Form 3 OKYO Pharma Ltd For: Mar 18 Filed by: Mantelli Flavio

Wed, 17 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260617/26660080.html

Form 4 OKYO Pharma Ltd For: Jun 08 Filed by: Shah Keeren Rameshchandra